Condition: Systemic Lupus Erythematosus · Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
To assess the efficacy and safety of TQH3906 in treating systemic lupus erythematosus.
This description comes directly from the study's public registry record.
Zhanguo Li, Doctor · 13910713924 · li99@bjmu.edu.cn
Always discuss trial participation with your own doctor first.
| The First Affillated Hospital of Bengbu Medical Universit | Bengbu, Anhui, China | Not Yet Recruiting |
| Bozhou People's Hospital | Bozhou, Anhui, China | Not Yet Recruiting |
| Beijing Chao-Yang Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Southwest Hospital, Third Military Medical University (Army Medical University) | Chongqing, Chongqing Municipality, China | Not Yet Recruiting |
| Gansu Provincial People's Hospital | Lanzhou, Gansu, China | Recruiting |
| The Third Affiliated Hospital of Sun Yat-sen University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Jiangmen Central Hospital | Jiangmen, Guangdong, China | Not Yet Recruiting |
| Shenzhen Second People's Hospital | Shenzhen, Guangdong, China | Not Yet Recruiting |
| The Second Affiliated Hospital of Guangxi Medical University | Nanning, Guangxi, China | Not Yet Recruiting |
| The First Affiliated Hospital Of GuangXi Medical University | Nanning, Guangxi, China | Not Yet Recruiting |
| The Affiliated Hospital of Zunyi Medical University | Zunyi, Guizhou, China | Not Yet Recruiting |
+ 23 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.